Integra Foundation Competitors

Origin Sciences develops and manufactures innovative diagnostic tools and assays that enable the detection, diagnosis and monitoring of gastrointestinal diseases. The Oricol™ sample collection device is Origin’s flagship product to enter the in vitro diagnostic market, which enables convenient and effective clinical sampling of mucocellular material from the rectum. Using the Oricol™ technology, Origin Sciences is developing a portfolio of assays and seeking collaborations to develop high-value tests for the GI market. Currently in development are tests for colorectal cancer (CRC) and Inflammatory Bowel Disease (IBD). Origin Sciences’ products are developed and manufactured within quality systems accredited to ISO 13485. Founded in 2004, Origin Sciences is based in the UK, with a laboratory in Cambridge and offices in London. Origin Sciences aims to be at the forefront of scientific breakthroughs in the investigation of gastrointestinal diseases.

Healionics is addressing the critical need for safer, more reliable means of bloodstream access to perform dialysis in patients with kidney failure. Our STARgraft vascular graft (synthetic blood vessel) is designed to resist the problems of occlusion and infection suffered by current devices. We also have an exciting product pipeline based on our platform STAR® biomaterial, which has a unique ability to prevent two serious problems that affect all implantable devices: scarring and infection. The company is currently conducting human studies of STARgraft and has 36 patents issued or pending.

Our mission is to develop and market breakthrough products, which will enhance the practice of orthopaedic surgeons and associate healthcare professionals, and thus, the quality of life of their patients.